These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 21434804)

  • 1. Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations.
    Burt D; Mallett C; Plante M; Zimmermann J; Torossian K; Fries L
    Expert Rev Vaccines; 2011 Mar; 10(3):365-75. PubMed ID: 21434804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.
    Treanor J; Nolan C; O'Brien D; Burt D; Lowell G; Linden J; Fries L
    Vaccine; 2006 Jan; 24(3):254-62. PubMed ID: 16129526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
    Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age.
    Roman F; Vaman T; Kafeja F; Hanon E; Van Damme P
    Clin Infect Dis; 2010 Sep; 51(6):668-77. PubMed ID: 20687838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children.
    Scheifele DW; Ward BJ; Dionne M; Vanderkooi O; Langley JM; Dobson S; Li Y; Law B; Halperin SA;
    Pediatr Infect Dis J; 2011 May; 30(5):402-7. PubMed ID: 21178654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v, in Stockholm County, Sweden.
    Ortqvist A; Berggren I; Insulander M; de Jong B; Svenungsson B
    Clin Infect Dis; 2011 May; 52(10):1203-11. PubMed ID: 21507917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Fang F; Zheng M; Chen Z
    Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal immunity and nasal influenza vaccination.
    Rose MA; Zielen S; Baumann U
    Expert Rev Vaccines; 2012 May; 11(5):595-607. PubMed ID: 22827245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children.
    Meier S; Bel M; L'huillier A; Crisinel PA; Combescure C; Kaiser L; Grillet S; Pósfay-Barbe K; Siegrist CA;
    Vaccine; 2011 Apr; 29(19):3548-57. PubMed ID: 21419775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination.
    Petersson P; Hedenskog M; Alves D; Brytting M; Schröder U; Linde A; Lundkvist A
    Vaccine; 2010 Sep; 28(39):6491-7. PubMed ID: 20637767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody response after a single dose of an AS03-adjuvanted split-virion influenza A (H1N1) vaccine in heart transplant recipients.
    Meyer S; Adam M; Schweiger B; Ilchmann C; Eulenburg C; Sattinger E; Runte H; Schlüter M; Deuse T; Reichenspurner H; Costard-Jäckle A
    Transplantation; 2011 May; 91(9):1031-5. PubMed ID: 21358365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
    Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
    Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines against influenza A (H1N1) pandemic.
    Valdespino-Gomez JL; Garcia-Garcia L; de León-Rosales SP
    Arch Med Res; 2009 Nov; 40(8):693-704. PubMed ID: 20304259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F; Vaman T; Gerlach B; Markendorf A; Gillard P; Devaster JM
    Vaccine; 2010 Feb; 28(7):1740-5. PubMed ID: 20034605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.